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Introduction
The ovaries are the female reproductive organs that are located on either side of the
uterus. They contain eggs and secrete hormones that are critical for female
reproduction. Each follicle consists of an egg at the center, surrounded by multiple
layers of somatic cells. These eggs undergo various stages of development wherein the
follicular structure matures as a whole; the hormones and growth factors secreted by
the somatic cells are essential for the maturation of the egg while the signaling
molecules produced by the egg are crucial for somatic cell proliferation and follicle
maturation and development.
Thus, mammalian ovarian follicle formation and development involves the establishment
of the initial follicle pool, follicle growth, proper maturation of eggs, and timely production
and release of hormones and the mature eggs. This process is essential for propagation
of the species as well as for development and homeostasis of the female reproductive
system[1]. Abnormalities in the regulation and development of ovarian follicles such as
inadequate maturation of the follicle due to inadequate cell-cell interactions and
signaling between the somatic cells and the egg can lead to infertility and ovarian
diseases, for instance Premature Ovarian Failure (POF), Polycystic Ovary Syndrome
(PCOS) and ovarian cancer.
These diseases lead to a loss of fertility due to the formation of immature or unhealthy
follicles and/or oocyte development. Both intraovarian and extraovarian factors play a
role in regulating the development of follicles. However, factors involved in follicular
growth and survival are not well defined. Recently, studies have suggested that the
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potent morphogen retinoic acid (RA) plays a role in the development of a healthy
ovary[1, 2]. However, the underlying mechanism is not understood. Germ cells in the
fetal ovary undergo sex-specific entry into meiosis, the initiation of which is thought to
be mediated by selective exposure of fetal ovarian germ cells to retinoic acid[2].
Nevertheless, the timing and regulation of meiosis vary amongst the sexes. It was
determined that high levels of RA were necessary for initiation of meiosis in the ovary
and the testes; however, while RA is required for germ cell development in the
embryonic ovary, it is required during the juvenile and adult stages of testicular
functioning[3, 4]. Cyp26b1, a member of the Cyp450 family of enzymes degrades
retinoic acid in the ovary and the testes thereby limiting gonadal development [1, 3, 5].
However, information about the role of RA and Cyp26b1 in the gonads is limited. It is
therefore necessary to further elucidate the roles of both RA and Cyp26b1 in ovarian
and follicle development.

The purpose of this study is to examine the roles of Cyp26b1 and RA in mouse ovarian
follicle development. This will be done by performing in vitro follicle culture and ovary
culture with treatments including retinoic acid, the Cyp26 inhibitor R115866 and the RA
metabolism inhibitor Liarozole and monitoring their effects on follicular and ovary
growth. We expect the findings from this study to contribute significantly to infertility
treatments and disease prevention, as being able to successfully grow follicles invitro
could help the large population of women whose difficulty with conceiving is due to an
immature and underdeveloped follicle pool.
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Review of Background literature

Ovarian follicle development in mammals: The ovarian follicle is the functional unit of
the ovary. It consists of somatic cells that surround an oocyte. The primary role of the
follicle is to support oocyte development and to produce hormones that control the
female reproductive cycle. The follicles undergo a process known as folliculogenesis
which describes the development and maturation of ovarian follicles growing from an
immature primordial stage into larger more developed follicular stages that ultimately
leads to ovulation (Table 1). At birth, human ovaries contain a fixed number of
immature, primordial follicles [62]. After puberty and coinciding with menarche, a small
number of follicles begin to mature to larger follicles that will end in either death or
ovulation. During post-pubertal follicular development, primordial follicles that have
begun development undergo a multitude of changes that are morphological as well as
hormonal and are essential for ovulation. This includes the primordial follicles
transitioning to primary, secondary, tertiary, and antral stages of development. Tertiary
and antral follicles depend on hormones that are circulated in the blood such as
estrogen, progesterone, Follicle Stimulating Hormone (FSH) and Luteinizing Hormone
(LH) causing a substantial increase in their growth and development. During each
menstrual cycle, only one follicle is selected for ovulation. This follicle ruptures and
discharges the oocyte ending its folliculogenesis[6] (Figure 1).

During folliculogenesis, the somatic cells differentiate into granulosa cells and theca
cells. Both these cell types are essential for follicle growth and development. Thecal
cells appear as the follicles enter into a more advanced stage of development such as
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the tertiary stage. They produce androstenedione that is used as a substrate by
granulosa cells to produce estradiol, under the influence of FSH. Theca cells also
contain LH receptors while granulosa cells contain FSH receptors. The hormones
produced by these cells as well as the receptors present on them are essential for cell
interactions within the follicles that are necessary for follicle development and growth.

Stage

Description

Primordial

Small and have an oocyte surrounded by a single
layer of squamous granulosa cells.

Primary

An enlarged oocyte surrounded by either a single
layer of cuboidal granulosa cells or a single layer of
mixed cuboidal and squamous granulosa cells.

Secondary

An enlarged oocyte surrounded by two or more layers
of cuboidal granulosa cells but have no fluid-filled
antrum.

Tertiary

An oocyte surrounded by layers of cuboidal granulosa
cells that contain one or more small antra.

Antral

An oocyte enclosed by cumulus cells and a single
large antrum surrounded by a single layer of cuboidal
granulosa cells.

Table 1: Different stages of follicle development in the mammalian ovary [7]
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FIG. 1: Folliculogenesis- Maturation and development of follicles until ovulation.
Ovarian follicles undergo morphologic and endocrinologic changes during the menstrual
cycle. The follicles form from Primordial germ cells that undergo various stages of
development that include the earlier stages of development that include the primary and
secondary stages of development and the more advanced stages of follicle
development like the tertiary and antral stages of follicle development before the oocyte
is mature enough to be released from the follicular structure, while the follicle undergoes
degradation to form the corpus luteum. This image is adapted from: Lamb,
M.M.M.D.J., Nature Medicine, 2008 [7]
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Ovarian diseases: There are several diseases that affect the ovary. These diseases
lead to low ovarian stimulation that results in an immature oocyte pool that require a
regimen that includes hormones, growth factors and vitamins to support the growth and
development of the immature oocytes.

Among these diseases, polycystic ovary syndrome (PCOS), premature ovarian failure
(POF) and ovarian cancer are three major diseases that affect a significant number of
women and are the leading causes of infertility. PCOS is a common cause of
anovulation and infertility among women of reproductive age. Women are usually
diagnosed when in their 20s or 30s, but polycystic ovary syndrome may also affect
teenage girls. The symptoms often begin when a girl's periods start [8]. It is a condition
in which there is an imbalance of a woman's sex hormones. Hormones help regulate the
normal development of eggs in the ovaries during each menstrual cycle. Hormonal
imbalances which include excessive production of LH and testosterone result in
menstrual irregularities and excessive production of testosterone also leads to acne and
hirsuitism. Most, but not all, women suffering from this disorder have enlarged and
containing numerous small cysts located along the outer edge of each ovary (polycystic
appearance). These cysts are immature follicles that are developmentally arrested in
the early antral stage due to the hormonal imbalance. These changes also contribute
significantly to infertility.

POF refers to a loss of normal function of ovaries before the age of 40 which causes
infertility in these patients[9]. The ovaries fail to produce normal amounts of the
hormone estrogen or release eggs regularly. Infertility is a common result. This
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decreased functional capacity of the ovary which is also known as ovarian hypofunction,
may be caused by genetic factors such as chromosome abnormalities, or it may occur
with certain autoimmune disorders that disrupt normal ovarian function[10].

Ovarian cancer is a cancerous growth arising from the ovary. Ovarian cancer is the fifth
largest cause for death in women due to cancer. It has a high mortality rate due to the
fact that it can only be detected at the late stage of cancer development. Measures
taken to treat ovarian cancer greatly reduce the amount of the hormones estrogen and
progesterone circulating in the body and affect follicle maturation and growth, which
causes infertility[11].

As previously mentioned, low ovarian stimulation is often the cause of these disorders
and therefore, conventional methods used to assist reproduction aren’t successful.
Thus, these women need to resort to in vitro fertilization wherein an egg is fertilized by
the sperm in vitro, or outside the body. This method involves the removal of a healthy
and mature ovum from the woman’s ovaries to allow for successful fertilization by a
sperm in a laboratory setting. However, women suffering from these diseases suffer
from an immature oocyte pool and these oocytes require in vitro maturation in order to
be developmentally competent for successful fertilization. Thus, traditional IVF protocols
need to be modified in order to incorporate hormones, growth factors and vitamins in
the medium, which are essential to bolster the competence of the immature oocytes for
fertilization and embryogenesis[12].
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Retinoic Acid: All trans retinoic acid, the active derivative of Retinol, is a naturally
occurring retinoid responsible for growth and differentiation in mammals. Retinol, which
is also known as Vitamin A is found in various foods such as carrots and spinach. It is
believed that retinol, the form of retinoic acid that is found in the plasma, is converted to
RA when taken up by the cells. RA can either act as a paracrine or autocrine moleculeIn the paracrine model, RA is produced in one cell but exerts its effects in another target
tissue, or is taken up by a non-target tissue where it is metabolized. In the autocrine
model, RA is produced in the same cell where it exerts its action and is metabolized[3,
13].
RA acts as a signaling molecule and exerts its activity through binding with transcription
regulatory factors, known as the RA receptors including RAR-α, RAR-β and RAR-γ.
These receptors are located in nucleus. Upon binding to the RARs, the receptor-ligand
complex then binds with the Retinoid X receptors (α, β, γ) to form a heterodimer that
binds to the Retinoic Acid Regulatory Element within the DNA, which stimulates a
cascade of events that results in the recruitment of transcriptional coactivators and can
either repress or activate the transcription of target genes that encode for proteins
involved in cell differentiation and development [14](Figure 2). 532 genes have been
identified to be regulatory targets of RA, which include Foxa1, Egr1, Tgm2, Pck1 that
are involved in differentiation and growth [67].
Although RA is required for development, it is not produced by the cells of the body at
all times. Retinol is secreted by the liver and is transported to the blood via serum
retinol-binding protein (RPB4) for conversion to RA. The cells also contain retinol-
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binding proteins (CRBPS) that facilitate the oxidation of retinol to retinaldehyde by RDH
while RALDH is responsible for the conversion of retinaldehyde to RA[14](Figure 2).

FIG. 2: Mechanism of Retinoid signaling. Retinol is taken up from the blood and
binds to the cellular retinol binding proteins present in the cytoplasm of the cells. Retinol
dehydrogenase metabolizes retinol to retinal and retinal is oxidized to retinoic acid via
cellular retinoic acid binding protein. Retinoic acid then enters the nucleus and binds to
retinoic acid receptors RAR and RXR which heterodimerize and bind to the Retinoic
Acid Response Element (RARE) in the DNA which turns on the transcription of genes
involved in growth and differentiation[15].
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Retinoic acid is required for various biological processes such as maintaining healthy
skin, regulation of apoptosis, maintenance and regulation of the immune system and the
development of the placenta and embryo development. In addition to its vital role in
development, RA is often used to treat patients with severe acne (due to its beneficial
effects on the skin), psoriasis and certain kinds of leukemias.
Studies have shown that a slight increase in RA may lead to malformations including
cleft palate, neural tube defects, heart defects[16] and limb malformations[13, 17]. On
the other hand, Vitamin A deficiency decreases immunity due to impaired T celldependent antibody responses[18] as well as a decrease in the number and function of
the natural killer cells[18, 19]. This can lead to death due to infection. RA is also
required for the maintenance of proper brain function and a decrease in RA leads to
memory loss and increased risk of Alzheimer’s disease[20, 21].
The levels of Vitamin A within the cells are tightly regulated. If the levels become too
high, it is degraded by the Cyp26 enzymes, a member of the Cyp450 family of
enzymes. Cyp26a1 is present in adult and embryonic tissues and is responsible for the
degradation of RA in cells such as those that make up the nervous system, the liver and
skin cells, to bring it back to threshold levels. When the levels of Vitamin A drop too low,
the Fibroblast growth factors (FGF) prevent the rapid degradation of RA[22]. Thus, both
Cyp26a1 and FGF work in concert to keep RA concentrations at optimal levels.

Role of Retinoic acid in the gonads: The development of mammalian fetal germ cells
along spermatogenic and oogenic pathways is controlled by signals from the
3

surrounding gonadal environment. Later stages of ovarian follicle development are
regulated by multiple hormones, including FSH and LH that are secreted by the pituitary
gland. However, a multitude of autocrine and paracrine non endocrine molecules such
as C-type natriuretic peptides, insulin growth factor-1, the TGF-β family as well as
fibroblast growth factors and Wnts are also essential for the maintenance of optimal
follicle growth [23, 66]. An additional growth factor that has been suggested to play a
role in ovarian development is retinoic acid[3].
Primordial germ cells are the embryonic precursors of sperms and eggs in the adult
organism. The initiation of meiosis is thought to be mediated by selective exposure of
the fetal ovarian germ cells to retinoic acid[24]. This was determined by detecting the
expression of retinoid synthesizing enzymes Aldh1a2 and Aldh1a3 in fetal mouse
ovaries. The expression of genes encoding RAR and RXR proteins in the ovary with
localization in the nucleus further indicates the role of RA signaling in germ cell
development which may be responsible for the regulation of germ cell survival or
proliferation[25]
RA induces entry into meiosis in the ovary at around 13.5 days postnatal. The germ
cells in the mouse ovary then stop proliferating and enter into their first meiotic division.
Studies performed previously show that exogenous RA added to rat XX germ cells in ex
vivo cultures accelerates their entry into meiosis, confirming the role of RA in meiosis in
the mouse ovary[2, 26]. In addition, previous studies conducted in oocytes isolated from
mice show that oocytes treated with RA have significantly higher meiotic competence
than the control group[12]. Unlike extensive studies carried out on mouse testes, the
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absence of RA and the effects of its degradation on meiosis in the ovaries have not
been elucidated.
Entry into meiosis is sex-specific with respect to the timing where male mice undergo
meiosis postnatally, wherein it begins at the time of reproductive development and
continues until puberty and throughout adulthood. Studies have indicated that the role of
RA in the reproductive health of the male is crucial and it can be detected at all times in
the testis except during embryonic development. Spermatogenic arrest is observed in
adult males in the absence of RA. Cyp26b1 was also found to catalyze the degradation
of RA which led to the inhibition of meiosis in the embryonic testis [4, 5, 27].

It has been demonstrated that an increase of antioxidants in culture and maturation
medium or embryo culture in a reduced O2 atmosphere could assist in vitro survival of
embryos in a variety of species. A number of studies have shown that retinoids
participate in a biological anti-oxidant network and are important regulators of redox
signaling pathways. Retinol derivatives can quench oxygen molecules and interact with
other antioxidant compounds. It has been shown that RA could protect oocytes against
oxidative stress induced by apoptosis[63, 64].

More specifically, Cyp26b1 mRNA and protein levels of Cyp26b1 were detected in
primordial follicles in different stages of follicle development at the different postnatal
development stages, namely days 1, 6, 10 and 20, with higher levels in the testis than
the ovaries. In addition, it was seen that RA and the Cyp26b1 inhibitor, R115866,
significantly stimulated the proliferation of granulosa cells dose dependently[1]. In order
to study the direct effects of Cyp26b1, cells were transfected so as to overexpress
3

Cyp26b1. When a transient transfection efficiency of 60-90% of Cyp26b1 was achieved
in granulosa cells (which was confirmed by detecting protein levels via Western Blot), a
decrease in living granulosa cell numbers and an increase in apoptotic cells was
observed. Conversely, an experiment was performed wherein Cyp26b1 expression was
knocked down in granulosa cells using siRNA. A decrease in Cyp26b1 expression
promoted granulosa cell proliferation, which was detected by quantifying BrdU
incorporation in the cells. These studies further elucidate the importance of RA in ovary
development, which provide credence to further studies in the field (unpublished data).

Imbalances, Dysfunctions and the Importance of RA signaling: In order to avoid both
deficiency and toxicity it is important to maintain the levels of RA within a narrow range.
Addition of Vitamin A in embryos by the implantation of RA impregnated beads has
been demonstrated to induce teratogenic effects and alterations in organogenesis [28].
However, rather than studying the effects of teratogenicity of RA to determine its
physiological role, loss-of-function studies are more valuable in determining the normal
function of RA during organogenesis.
Vitamin A deficiency in male rats causes germ cell degeneration while female rats fed
with a Vitamin A deficient diet were unable to reproduce [29]. When RA is added in an
organ culture system, it decreases apoptosis and increases the number of healthy
oogonia, oocytes and primordial follicles. Fetal ovaries cultured without RA do not show
DNA replication. These studies confirm that RA is in fact a potent stimulator of germ cell
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proliferation[30]. Therefore, RA is a powerful survival factor and is a mitogen that also
functions as an antiapoptotic and pro-stimulatory factor in female germ cells[30].
ALDH1 (aldehyde dehydrogenase I) is a member of the aldehyde dehydrogenase family
member and is responsible for the oxidation of aldehydes to acids. It is responsible for
irreversible oxidation of retinal to retinoic acid. ALDH1 expression is highest in normal
human and mouse ovary and was found to be altered in malignant tumors[31],
suggesting that ALDH1 may play a significant role in ovarian cancer. It was seen that
ALDH1 m RNA and protein expression was lower in malignant ovarian tumors when
compared to normal ovaries or benign tumors[31]. As a result, enzyme activity was also
significantly reduced in malignant ovarian tissue when compared to benign ovarian
tumors or normal ovaries. Microarray studies also showed a downregulation of
ALDH1A1 gene expression in malignant ovarian tumors suggesting that ALDH1 plays a
functional role in normal ovarian physiology. ALDH1 levels are lower in less
differentiated malignant tumor cells when compared to differentiated malignant tumor
cells, indicating the importance of ALDH1 and RA in normal ovarian signaling[31].
Cyp26 enzymes: Plasma and tissue levels of RA are kept under tight homeostatic
control. RA signaling is negatively regulated via oxidation to an inactive metabolite,
which is initiated by the 4-hydroxylation of RA. This forms inactive metabolites and is
carried out by RA degrading enzymes. Although many microsomal P450 enzymes may
degrade RA, their specificity for RA is low. In contrast, the Cyp26 families of enzymes
have a higher specificity for RA and are responsible for its conversion to 4-hydroxy
retinoic acid, 8-oxoretinoic acid and 18-hydroxy retinoic acid[32]. These enzymes
contain a heme domain that act as a RA hydroxylase. Their expression is inducible by
3

RA and they in turn metabolize RA. The clones that were characterized and identified in
humans were Cyp26A1, Cyp26B1 and Cyp26C1. Cyp26a1 and b1 have a high
specificity for all trans RA [13, 33] although Cyp26c1 efficiently metabolizes both all
trans RA and 9-cis RA [34, 35]. Upon overexpressing Cyp26, it is observed that there is
an increase in the clearance of RA [35] while an addition of RA in vivo induces Cyp26a1
expression [36].
The discovery of the Cyp26 family was made when a strong correlation between Cyp26
expression and RARα levels was observed while Cyp26 expression was not detectable
when RARα levels were very low, suggesting that Cyp26 is a direct candidate target of
RARs. High RARβ levels are also associated with Cyp26 expression and RAR
dependent auto-induction of RA metabolism can induce Cyp26, which results in the
formation of 4-hydroxy RA as the first step in the breakdown of RA[37].
Of the three enzymes, Cyp26b1 was the most highly conserved between human,
mouse and zebrafish[38]. In humans, Cyp26A1 and Cyp26C1 are located on
chromosome 10 while Cyp26B1 is located on chromosome 2[39]. Cyp26A1 and
Cyp26B1 are essential for animal survival as the knockouts of these genes are lethal
whereas Cyp26C1 knockout animals are viable. Cyp26A1 knockout mice died midgestation and Cyp26B1 died shortly after birth, possibly due to respiratory failure. Both
sets of knockouts showed limb and facial deformities; while Cyp26A1 knockout mice
showed deformed tails, Cyp26B1 knockout mice also showed defects in limb
development[40, 41]. These differences can be attributed to the expression of the
enzymes during development. Cyp26A1 expression is involved in the development of
the hindbrain, vertebrae and tail and Cyp26B1 m RNA is more highly expressed in the
3

craniofacial, hindbrain, forebrain, spinal cord, lungs, kidneys, testis and skin. In adult
humans, Cyp26A1 expression is the highest in the liver, while Cyp26B1 is abundantly
expressed in the placenta, ovary, testes and brain[13].
When mice were treated with RA, an up-regulation of RA metabolism was observed
which is attributed to RA’s ability to auto-induce its own metabolism. Cyp26 induction
has been observed in RA treated mouse liver[36]. It is believed that RARs are
responsible for inducing Cyp26[13].
Oral treatment of rats with the Cyp26 inhibitor such as R115866 increases plasma and
tissue levels of RA and produces effects similar to those of RA[32]. Since the ovaries
have a high capacity to produce RA, it can be hypothesized that inhibition of Cyp26mediated RA metabolism would increase the endogenous levels of retinoic acid and
mimic the effects of retinoic acid in the ovary.

Retinoic Acid Metabolism Blocking Agents: The major role of Cyp26 is to degrade RA,
thereby regulating RA levels in the cell[37]. RA has several therapeutic applications,
which include its use in the induction of cytodifferentiation and suppressing the
proliferation of promyelocytic leukemia[42], treatment of severe nodular acne[43] as well
as treatment of psoriasis and some forms of ovarian cancer[44]. However, autoinduction of RA clearance during therapy leads to a clinical challenge due to Cyp26
clearance of RA. To overcome this obstacle, it is now common to co-administer Cyp450
inhibitors along with RA to decrease its clearance. This has led to the development of
structural analogs of RA that were modified to inhibit RA metabolism. These drugs were
3

named Retinoic Acid Metabolism Blocking Agents (RAMBAs) which serve to maintain
effective RA concentrations by inhibiting the metabolism of RA[13]. Two examples of
RAMBAs will be discussed below.
a. LIAROZOLE
Liarozole is the most studied RAMBA which inhibits RA metabolism in vitro. It is a new
imidazole derivative that has antitumor properties[45]. Liarozole has been shown to be
effective against psoriasis. It has also been shown to decrease tumor growth in
androgen dependent and independent rat prostate cancer. Liarozole is known to
decrease testosterone levels via inhibiting aromatase[45].
RA plays an important role in proliferation of epithelial tissue and has antitumoral
activity, and Liarozole inhibits several Cytochrome P-450 enzymes[45, 46]. Liarozole is
known for especially inhibiting 4-hydroxylase, which metabolizes RA. It has been shown
that when patients suffering from acute promyelocytic leukemia with retinoid resistance
were pretreated with Liarozole one hour prior to ingesting RA, there was a decrease in
RA catabolism and an increase in plasma RA, which may contribute to the antitumoral
activity of the compound[46]. It has also been shown that Liarozole by itself did not have
much of an effect on the proliferation of MCF-7 cells but it did significantly potentiate the
antiproliferative effect of RA by more than 10-fold. This showed that although RA and
Liarozole were active in different ways individually, in combination they showed
antiproliferative activity and that the potentiation of the effect of RA on the proliferation
of MCF-7 cells by Liarozole was also due to the prevention of the inactivation of RA due
to metabolism [45]. However, liarozole does not show Cyp isoenzyme specificity since it
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is also involved in testosterone synthesis. It is therefore important to carry out studies to
discover compounds that are Cyp26-specific inhibitors in order to mimic retinoidal
effects without the unwanted side effects associated with decreased testosterone
synthesis[32].
b. R115866
R115866 is a potent and selective inhibitor of the Cyp26 family of enzymes. The
chemical name of R115866 is (B)-N-(4-(2-ethyl-1-(1H-1,2,4 - triazol (1-yl) butyl) phenyl)
-2-benzothiazolamine. It is a selective Cyp26b inhibitor and is therefore less likely to
cause undesired side effects. The in vivo activities of R115866 include inhibition of RA
metabolism when Cyp26 enzymes were coincubated with R115866 and increased
systemic levels of RA. R115866 also illicit a dose dependent increase of hepatic Cyp26
mRNA expression. In addition, a single dose of R115866 in rats produced a discernible
surge of endogenous RA levels in the plasma, skin, kidney, spleen and fat. This
suggests that R115866 delays the metabolism of RA and increases local levels in
tissues where RA is metabolized [32]. It not only increases endogenous plasma and
tissue RA levels by delaying RA metabolism but also mimics the effects of RA [47].Oral
treatment of R115866 in rats results in retinoidal effects like suppression of vaginal
keratinization and increased pinnal hyperplasia [47].
Conversely, studies performed to determine the effect of RA on cell lines have
demonstrated that the administration of RA to human and mouse cell lines results in
Cyp26 expression and leads to an increase in Cyp26 mRNA levels in the liver[32].
Since CypP26 mRNA and RA activity are directly related, it can also be said that RA is
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a strong inducer of Cyp26 mRNA expression and enzyme activity[32]. It would therefore
be interesting to study the effects of R115866 and RA in follicle development.

Mice as a model for ovarian follicle development studies: Mice are the most commonly
used mammalian model for laboratory research. They are relatively easy to maintain
and handle, reproduce quickly, and share a high degree of similarity with humans in
terms of morphology and hormone/gene regulation. The mouse genome has been
sequenced, and many mouse genes have human homologues. The mouse model has
also been important in revealing some essential principles of follicle growth, assembly
and the role of growth and differentiation factors

Follicle culture as an in vitro model: Experiments in mice using the methodology of in
vitro follicle culture have shown that long term follicle culture does not affect
imprinting[48]. Previous studies on ovarian follicle development have made use of
various in vivo and in vitro systems, and the latter includes follicle cultures and cell
cultures. Some of the in vitro studies involve the use of theca, oocytes or granulosa cell
cultures that eliminate the otherwise complicated in vivo effects of hormones and other
growth factors that could potentially interfere with the studies. However, these studies
do not take into account cell-to-cell interactions that are important for development and
growth. Granulosa cells, theca cells and oocytes within the follicles show cell-cell
interactions which influence the growth and viability of these follicular cells.
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Nourishment and the exchange of regulatory factors from granulosa cells to the oocyte
are essential for oocyte development, wherein the granulosa cells act as nurse cells[49].
Follicular somatic cells promote or arrest the progression of meiosis and determine
oocyte competence to allow for fertilization. Oocyte growth is under the control of
somatic cell signaling as they continue to grow once they acquire the competence to
resume meiosis[50]. On the other hand, oocytes regulate the growth and development
of granulosa cells. Oocytes play an integral role in the formation and the activation of
the primordial germ cell pool in the ovaries [51]. Oocytes also play an important role in
the development of the follicles to more advanced stages such as tertiary and antral
stages of development [52, 53], and in granulosa cell proliferation and differentiation
and ovulation [54-56]. Thus, the signals exchanged between the somatic cells and
oocytes are crucial for the initiation and coordination of differentiation in the oocyte and
somatic cells. These signals not only promote oocyte but also granulosa cell growth,
thereby orchestrating follicle growth as a whole [57, 58]. Therefore, follicle culture has
the advantage in knowing the effects of drugs on these cells in an environment that
simulates

the

environment

in

the

ovary

without

the

interference

of

other

hormones/growth factors.
In vitro follicle culture will provide us with a better understanding of the mechanisms by
which follicle growth and oocyte maturation take place. It also has clinical applications
such as cryopreservation of ovarian tissue that is used for the restoration or
preservation of fertility. The major goals of in vitro culture systems include providing
support to the somatic cells so as to maintain the cell-to-cell interactions between the
somatic cells and the oocytes, and permeability to the media where hormones can
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diffuse into the follicle and factors secreted by the follicle can be released into the media
[48]. Two types of in vitro systems follicle culture have been developed to grow follicles,
-the two-dimensional and three-dimensional system.
The three-dimensional systems are successful in supporting oocyte maturation in
growing follicles. It provides the mechanical support that is needed to maintain cell-tocell interactions within the follicle. The matrix or hydrogel that is used is an alginate
system, an inert algae-derived polysaccharide that undergoes gelation with calcium
ions. This system has the rigidity to maintain the 3D structure and at the same time,
allows for the expansion of the follicle due to oocyte growth and granulosa cell
proliferation[48]. This system also mimics the environment of the ovary, which thereby
supports the growth and development of the follicles isolated from a variety of animals.
Till date, successful folliculogenesis has been achieved in follicles obtained from mice,
primates, cows and humans using the 3D alginate system [59]. Follicles grown in the
alginate system have also been proven to be meiotically competent that were readily
fertilizable and resulted in the birth of viable offspring in mice[60].

Two-dimensional systems are commonly used to grow primary and secondary follicles
that have been mechanically isolated from mice [59]. When the follicles are isolated
from their natural environment, they are exposed to various physical restrictions such as
oxygen tension, temperature and nutrient availability as well as uptake that might pose
various obstacles in their growth. It is therefore necessary to provide these follicles with
ambient temperature and the appropriate nutrient and oxygen requirements so as to
mimic the natural environment in vivo, thereby allowing for its growth and development
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in vitro. In order to grow follicles in 2D culture, FBS is commonly used in combination
with insulin, selenium and transferrin (ITS). Alpha minimal essential medium is also
used predominantly along with FSH to promote follicular development and survival[48].
In vitro studies performed in 1996 that lead to the production of a live mouse from an
oocyte that developed from the primordial follicle stage to a developmentally competent
stage in culture gave hope to the field of in vitro follicle culture[48, 58].
Although 3D culture is extensively used to culture follicles that were meiotically
competent and have provided viable offspring, I chose to use the 2D culture system for
my studies as the aim of my studies is to perform a quick study on the growth profile of
the follicles when treated with RA and RAMBAs and the 2D culture system is simple,
fast and a more convenient method for a screening process.
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Experimental Designs and Methodology
Animals
CD-1 mice were maintained in a temperature and light controlled environment and were
provided with food and water at all times. Animals were maintained and bred in
accordance with all federal and institutional guidelines[1].

Follicle cell culture, collection and treatment
The following method is adapted from the very well established follicle culture handbook
provided by Dr. Teresa Woodruff’s Laboratory at Northwestern University, Chicago.
Six 12-16 day old female CD-1 mice were euthanized using CO2 asphyxiation. The
ovaries were then removed from the animals. The roughly dissected ovaries were then
placed into a 35mm dish with dissection media that consisted of 30 ml L15 (98.52%v/v),
150 µL of Pen (0.49%v/v) and 300 µL of FBS (0.99%v/v). The ovaries were cleaned
free of fat, bursa and uterus under a dissecting microscope using dissection scissors.
The cleaned ovaries were transferred into a new 35 mm dish containing maintenance
media that consisted of 30 ml αMEM (98.52%v/v), 150 µL of Pen-Strep (0.49%v/v) and
300 µL of FBS (0.99%v/v). Follicles were mechanically isolated from the ovaries using 2
insulin syringes. Twenty to forty secondary follicles per ovary were collected. The
development stage of these follicles was determined by their sizes, all of which ranged
between 100-180 µm in diameter. Intact follicles were transferred to 2.5 ml of
maintenance media that consisted of 98.52%v/v of αMEM, 0.49%v/v of Pen-Strep and
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0.99%v/v of FBS. The health of these follicles was evaluated. The follicles that
contained proper amount of granulosa cells, showed proper association between oocyte
and granulosa cells, and had round oocytes were considered healthy. The follicles were
maintained in growth medium. Healthy follicles were plated into a 96 well plate with one
follicle per well, using only the 24 wells at the center of the plate in order to prevent
evaporation of the media. Each well contained 100 µl growth media that was made by
combining 27 ml αMEM (89.9 %v/v), 30 µL of ITS (0.099 %v/v), 3 ml of FBS (9.99
%v/v), and 300 mIU rhFSH. 50 µl of the media was replaced every day with fresh
media. The follicles were measured and imaged within 10 minutes of being taken out of
the incubator. Cultured follicles were given the following treatments; all-trans RA, 0.7
µM; R115866, 0.7 µM, FSH, 100mIU/ml or Liarozole, 1 µM. These concentrations were
chosen as the physiological concentrations of RA in mouse tissues were found to be
0.05-1 µM [65]. Thus, the doses were chosen to fit within the observed range and higher
concentrations were chosen to determine the effects of supplemental RA on growth and
development. The treatments were given every 24 hours for 4 days for follicle growth
and survival assays[1]. A second set of experiments involved the following treatments;
FSH, 100mIU/ml, FSH, 100mIU/ml plus Liarozole, 1 µM, Liarozole, 0.01 µM, Liarozole,
0.1 µM, Liarozole, 1 µM and Liarozole, 10 µM. Liarozole was found to inhibit RA
metabolism and promote proliferation via a retinoid mimetic pathway [45]. However, not
much is known about the role of Liarozole in ovarian development. Thus, studies using
a wide range of concentrations were performed in order to study the effects of the
various concentrations of Liarozole in the ovary.
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For all treatments, a total of 3 replicates (n=3) were carried out and for each
experimental setup, controls were set up using the same number of follicles but treated
with FSH, 100 mIU/ml which was used as the positive control, or DMSO, which was
used as the control[1] (Fig.3).
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Fig. 3: Follicle cell culture methodology and treatment Follicles are collected from
ovaries harvested from female CD1 mice that are day 12-16 and are cultured in media
for four days under the various treatment groups (as shown), wherein the follicles are
imaged and measured and half the media is replaced with fresh media every 24 hours.
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Monitoring follicle and oocyte growth and follicle morphology
Cultured follicles were measured daily for diameter and were monitored using dissection
microscopy for any changes in size, morphology as well as the presence of oocyte in
the follicle (health status). The follicles were also monitored for maintenance of the
integrity of the cells within the follicle.
This was done to help establish and determine the healthy growth of the follicle and the
oocyte which could serve as an additional method to establish the relationship of these
drugs on follicle development [61].

Ovary culture, collection and treatment
Breeding cages were set up and a vaginal plug was observed daily until a plug was
visible. Pregnant mice deliver pups between day 19-19.5 dpc. In the meantime, 50 ml of
ovary culture media was prepared that consisted of 2X DMEM/F12 (50%v/v), 120 mg
sodium bicarbonate, 2.5 mg ascorbic acid, 50 mg Albumax 1 , 50 μl insulin (10 mg/ml),
275 μl transferrin (5 mg/ml), 500 μl BSA (100 mg/ml) and 0.25 ml Pen/Strep. The
volume was then raised to 50 ml with distilled water to pH 7.3. When the pups were
born, the females were removed from the litter. The pups were kept warm upon
separation. Before decapitation, 5 ml of the culture media was pipetted out of the stock
and aliquoted into four 1.2 ml tubes. DMSO, 7 μm, that served as the control, R115866,
7 μm, Liarozole, 1 μm and Retinoic acid, 7 μm were added to each aliquoted media
tube to serve as different treatment groups. 400 μl of the media was added from each
of the tubes to 3 wells each of a 24-well plate, except the tube that contained Retinoic
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acid. Since Retinoic acid is light sensitive, 400 μl of the media containing RA was added
to 3 wells in a separate 24-well plate and wrapped in foil to keep out the light. The
plates were then placed in the incubator to warm the media (37C, 5% CO2). In the
meantime, Millicell filters were removed under a laminar flow hood using forceps and
placed in a 60 mm dish. These filters were used in order to provide a semi permeable
membrane upon which the ovary was placed. Using the filter made it possible to allow
for ovary growth and development by allowing for unlimited oxygen and media access.
A sterile scalpel was used to cut the filters into 6 pieces. If the filters wrinkled, they were
made taut by using 2 pairs of forceps. Two filters were cut in order to obtain filters good
for 12 ovaries obtained from 6 females. The filters were then transferred to each of the
wells containing media using forceps. The plates were then replaced in the incubator.
Once the plates were ready, the culture media was transferred to 60 mm dishes. The
pups were then decapitated and a deep abdominal incision was made to make lateral
cuts on both sides. The pup was then placed on its back underneath a dissecting scope.
Forceps were used to locate the oviduct which was used to locate the kidney and the
ovary. A dissecting scissor was used to cut the area between the kidney and ovary. The
ovary was then placed in the culture media. Forceps and scissors were used to remove
the surrounding bursa/oviduct from the ovary to get the ovary as clean as possible. The
culture plate was then removed from the incubator and 5 μl of the media from the well
was added onto the floating filter, thereby creating a drop on the filter. The ovary was
transferred to this drop using 22 G needles as chopsticks to pick up and transfer the
ovary. This was repeated for all the ovaries. The ovaries were cultured for 4 days
wherein the media was replaced every day from underneath the filter as well as the
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drop on top of the filter that contains the ovaries (Fig.4). To fix the ovaries, forceps were
used to place the filter on top of the plate lid. PBS was flushed gently onto the filter to
dislodge the ovary from the filter which was then drawn up with a cut pipette tip. The
ovary was the transferred to a vial containing 1 ml of 10% formalin solution and was
fixed for 1 hour. It was then dehydrated 3 times for 20 minutes each in a tube containing
1 ml of 50% ethanol and then 2 times for 20 minutes each in 70% ethanol. The fixed
ovaries were then stored in 70% ethanol at 4C. The ovaries were embedded in paraffin
and histological sections in multiples of 5 were made for each ovary sample, wherein
every other slide was stained for morphological studies and every fifth section from
each ovary was used for counting. Sectioning and staining were performed by the
Histology Core Facility at Northwestern University, Chicago, IL.
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Fig. 4: Methodology of Whole Ovary Development Ovaries were dissected from new
born pups and cleaned of fat and bursa. The ovaries were then cultured for four days in
growth media containing the different treatments, and the media was replaced every 24
hours. After the fourth day, the ovaries were fixed and sectioned for counting and
immunohistochemistry.

3

Follicle Counting for Ovary Culture
Follicles were counted and identified from all the stained slides using the Image J
software. Follicles that contained two or more oocytes that shared a cytoplasm and
were not separated yet were considered to be oocyte nests. A follicle with one oocyte
surrounded by a single layer of flattened granulosa cells was identified as primordial
follicles, follicles with an oocyte surrounded by one layer of a mixture of flattened and
cuboidal granulosa cells were identified as B/C cells, and a follicle that contained two
oocytes was considered to be a dividing follicle. A follicle with an oocyte surrounded by
one layer of cuboidal granulosa cells was considered primary, and follicles with an
oocyte surrounded by two or more layers of granulosa cells were considered as
secondary. Follicles that contained an oocyte that did not look healthy were identified as
atretic follicles (Fig.5). Two follicles that were encapsulated within one membrane and
shared cytoplasm were categorized as dividing oocytes. Only follicles with clearly
stained oocyte nuclei were counted from every fifth section of each slide. The numbers
for each ovary were then summed up and the sums were multiplied by 5 in order to get
the total follicle count of the ovary [23].
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Fig. 5: Stages of follicle development in early ovary development The figure
depicts the various stages of development that are typical and not so typical (atretic
follicle) in early stages of ovarian development (follicle were imaged from ovary sections
as seen under the microscope).
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Immunohistochemistry
Slides were deparaffinized twice for ten minutes in xylenes. The slides were then
rehydrated for three minutes each in 100% Ethanol, 95% ethanol, 70% ethanol, 50%
ethanol and ddH20. Antigen retrieval was performed in a 0.1M sodium citrate solution by
microwaving for two minutes on high and seven minutes on low and then cooling in the
retrieval solution for twenty minutes. The slides were washed twice for fifteen minutes in
PBS-Tween to permeabilize and the sections were then encircled using a PAP pen. The
sections were then divided to different groups: experimental KI67, experimental CYP,
negative control CYP, experimental TUNEL and negative control TUNEL. The slides
were incubated in 3% Hydrogen peroxide in PBS for fifteen minutes (the negative and
experimental TUNEL samples were kept moist in PBS). The slides were then rinsed in
PBS briefly and the samples were blocked in Avidin for fifteen minutes. Again, the
negative and experimental TUNEL samples were kept moist in PBS. The slides were
rinsed briefly in PBS and the sections were blocked in Biotin for fifteen minutes wherein
the negative and experimental TUNEL samples were kept moist in PBS. Upon
completion of the fifteen minutes, the slides were rinsed briefly in PBS. The
experimental sections were then blocked in 10% serum in 3% BSA-PBS (rabbit serum
for CYP26b1 (Sigma) and goat serum for Ki67 assay (ab1667)) for one hour at 4C
(negative and experimental TUNEL samples are kept moist in PBS). The samples were
incubated overnight in primary antibody diluted in 3% BSA-TBS-10% serum at 4C
(1:100 dilution for goat antibody for Ki67 sample and 1:50 dilution for rabbit antibody
from Sigma for experimental CYP sample). Negative CYP was incubated with the
Blocking serum used previously and negative and experimental TUNEL samples were
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kept moist in PBS. The next day, the ABC reagent was then prepared by diluting 2
drops A and 2 drops B into 5 ml PBS and the reagent was kept on ice. The slides were
then rinsed three times for five minutes each in PBS-Tween. The slides were incubated
in secondary antibody conjugated to BIOTIN in 3% BSA-PBS for thirty minutes (1:1000
diluted biotinylated rabbit anti goat IgG for CYP26b1 and biotinylated goat anti rabbit
IgG for Ki67. Negative and experimental TUNEL samples were kept moist in PBS) after
which the slides were rinsed three times for five minutes each in PBS-Tween. Diluted
ABC reagents was added to CYP and Ki67 samples and incubated for thirty minutes
and negative and experimental TUNEL samples were kept moist in PBS for this period.
The slides were rinsed five times for five minutes each in PBS-Tween. The TUNEL
samples were incubated in label solution (negative control) and enzyme in label solution
(experimental sample) for one hour at 37C wherein negative and experimental CYP and
Ki67 samples were kept moist in PBS. In the last five minutes of the TUNNEL assay,
the PBS was wiped off from the CYP and Ki67 samples and these samples were
incubated with TSA. The samples were rinsed off three times for five minutes each in
PBS-Tween. The slides were then pat dry and DAPI was added as the mounting
medium. The slides were then sealed using a coverslip and nail polish.
Statistics
Follicle counting data are presented as the means ± se. For comparisons between the
treatment group and the negative control, a Student’s two-tailed t test was used. P <
0.05 was considered significant[1].
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Hypothesis

In order to determine the role of RA and Cyp26b1 on ovarian follicle development, I
propose to look at the effects of RA and RAMBAs Liarozole and R115866, in isolated
follicles, using the 2D culture system and monitoring the growth of the cultured follicles
daily. I hypothesize an increase in follicle growth in all treatment groups, with a greater
extent of growth in the groups treated with RAMBAs than RA treated follicles.

I also propose to look at the effects of RA, R115866 and Liarozole in whole ovary
culture wherein ovaries would be harvested from newborn mice and cultured for four
days in media containing RA, R115866 and Liarozole. As previously stated, Liarozole
was found to inhibit RA degradation and increase plasma RA [45]. It also potentiates the
effect of RA on proliferating MCF-7 cells [45] and although it does not show CYP
isoenzyme specificity, it would be interesting to determine the effects of Liarozole on
follicle growth and development.

A morphological and immunohistochemical analysis is used to gauge the effects of the
drugs on whole ovary development. I hypothesize effects similar to those that are
expected using the 2D follicle culture system, wherein ovaries treated with RAMBAs
would show a stronger development profile than ovaries treated with RA.
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RESULTS
Effects of RA, R115866 and Liarozole on the growth of in vitro cultured follicles
When follicles were isolated from day 15 CD-1 mice and grown in media for 4 days,
most follicles maintained their structural integrity in the growth media. Survival rates did
not differ significantly among different treatment groups during the first 2 days; however,
after 4 days of culture, follicle survival rate was decreased in the groups treated with
Liarozole and Retinoic acid when compared to the control (Fig. 6). The follicles that
were treated with 1 μM Liarozole, 0.7 μM Retinoic acid, 0.7 μM R115866 or 100 mIU/ml
FSH had linear growth curves and were significantly larger than follicles grown in control
media (Fig. 7). Follicles treated with Liarozole and FSH showed a a significant increase
in diameter while follicles treated with Retinoic acid showed a less, although significant,
increase in diameter.
The change in follicle growth could be attributed to variability within the assay. However,
the assay was validated by performing various replicates and pilot studies wherein
variability within replicates was minimized. It is important to note however, that
individual difference within pups and initial follicle diameter could cause variations, but
since follicle growth showed a similar trend for all replicates, the results can interpreted
to be biologically significant.
In order to further study the effects of these drugs on follicle growth, additional studies
were carried out wherein follicles were treated with varying concentrations of these
drugs to determine the dose-response of the drugs on follicle development.
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FIG.6: Survival rates of follicles treated with RA and Retinoic Acid Metabolism
Blocking Agents
Secondary follicles were isolated from mice at day 15 and cultured for 4 days with media
changes every day. The follicles were treated with 100 mIU/ml FSH, 0.7 μM R115866, 1 μM
Liarozole and 0.7 μM RA. Follicle survival was monitored daily.
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FIG.7: Growth Curves of follicles treated with Retinoic Acid and Retinoic Acid
Metabolism Blocking Agents
Secondary follicles were isolated from mice at day 15 and cultured for 4 days with media
changes every day. The follicles were treated with 1 μM Liarozole, 0.7 μM R115866, 0.7 μM
Retinoic acid or 100 mIU/ml FSH and follicle diameters were monitored daily. Statistical
significance was observed between different treatment groups as compared to the control
groups (*P <0.05, **P<0.005, n=24)
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EFFECT OF RA ON THE GROWTH OF IN VITRO CULTURED FOLLICLES
First, follicles were cultured and treated with 0.07 μM RA, 0.21 μM RA, 0.7 μM RA, 2.1
μM RA or 100 mIU/ml FSH. These follicles had linear growth curves and showed

variable and moderate growth as compared to follicles grown in control media (Fig. 8).
Follicles treated with 0.07 μM of RA showed a lower growth profile than the control.
Follicles treated with 0.21 μM RA and 0.7 μM of RA showed the best follicular growth
than the control that was significant at Days 3 and 4. A higher dose of RA (2.1 μM)
seemed to have a positive effect on follicle growth; however, the follicles showed a
decrease in growth that was comparable to that of the control on Day 4. As expected,
follicles treated with FSH showed significantly larger diameters (Fig. 8).
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FIG.8: Growth Curves of follicles treated with Retinoic Acid
Secondary follicles were isolated from mice at day 15 and cultured for 4 days with media
changes every day. The follicles were treated with increasing doses of Retinoic acid (0.072.1 μM) or 100 mIU/ml FSH and follicle diameters were monitored daily. Statistical
significance was observed between different treatment groups and the control groups (*P
<0.05, **P<0.005, n=24).
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EFFECT OF R115866 ON THE GROWTH OF IN VITRO CULTURED FOLLICLES
Most follicles that were isolated from day 15 CD-1 mice and grown in media containing
varying concentrations of R115866 for 4 days maintained their structural integrity in the
growth media. Survival rates didn’t differ significantly among the different groups during
the 4 days of culture; however, follicle survival was less in the group treated with 0.21
μM of R115866 when compared to the control (Fig. 9).

The follicles were cultured with 0.07 μM R115866, 0.21 μM R115866, 0.7 μM R115866
or 100 mIU/ml FSH. These follicles had linear dose-dependent growth curves and
showed significant growth when compared to the follicles grown in the control media
(Fig. 10). Follicles treated with 0.21 μM of R115866 showed the highest growth profile
amongst all treatment groups. As expected, FSH grew to more advanced stages of
growth with a significantly larger diameter (Fig. 10).
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FIG.9: Survival rates of follicles treated with RA and Retinoic Acid Metabolism
Blocking Agents
Secondary follicles were isolated from mice at day 15 and cultured for 4 days with media
changes every day. The follicles were treated with 100 mIU/ml FSH, 0.07 μM R115866, 0.21
μM R115866 and 0.7 μM R115866. Follicle survival was monitored daily.
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FIG.10: Growth Curves of follicles treated with Retinoic Acid Metabolism
Blocking Agent, R115866.
Secondary follicles were isolated from mice at day 15 and cultured for 4 days with media
changes every day. The follicles were treated with increasing doses of R115866 (0.07-0.7
μM) or 100 mIU/ml FSH and follicle diameters were monitored daily. Statistical significance
was observed between different treatment groups (*P <0.05, **P<0.005, n=24)
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EFFECT OF LIAROZOLE ON THE GROWTH OF IN VITRO CULTURED FOLLICLES
Most follicles that were isolated from day 15 CD-1 mice and grown in media containing
varying concentrations of Liarozole for 4 days maintained their structural integrity in the
growth media. Survival rates didn’t change significantly among the different groups
during the 4 days of culture; follicle survival was less in the groups treated with 1 μM, 10
μM of Liarozole and a combination of 1 μM Liarozole and 100mIU/ml of FSH, when

compared to the control after 4 days of culture (Fig. 11).
The follicles were also cultured and treated with 0.01 μM Liarozole, 0.1 μM Liarozole, 1
μM Liarozole, 10 μM Liarozole and 100 mIU/ml FSH. These follicles had linear dose

dependent growth curves and showed significant growth when compared to the follicles
grown in the control media (Fig. 12). What was interesting to note was that follicles
treated with the higher doses (specify what does that you are talking about here) of
Liarozole had a significantly larger diameter than FSH, which acted as a positive
control.
In order to determine if Liarozole and FSH have a synergistic effect on follicle growth, a
combination of both drugs was administered to the follicles. It was seen that there was a
synergistic effect of the combination wherein a combination of 1 μM Liarozole and 100
mIU/ml FSH had a greater effect on the growth of the follicles than did either drugs on
their own (Fig. 12).
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FIG.11: Survival rates of follicles treated with Retinoic Acid Metabolism Blocking
Agent, Liarozole.
Secondary follicles were isolated from mice at day 15 and cultured for 4 days with media
changes every day. The follicles were treated with increasing doses of Liarozole (0.01-10 μM),
Liarozole (1 μM) and FSH (100 mIU/ml) or 100 mIU/ml FSH, and follicle survival was
monitored daily.
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FIG.12: Growth Curves of follicles treated with Retinoic Acid Metabolism
Blocking Agent, Liarozole.
Secondary follicles were isolated from mice at day 15 and cultured for 4 days with media
changes every day. The follicles were treated with increasing doses of Liarozole (0.01-10
μM), Liarozole (1 μM) and FSH (100 mIU/ml) or 100 mIU/ml FSH, and follicle diameters
were monitored daily. Statistical significance was observed between different treatment
groups (*P <0.05, **P<0.005, n=24)
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Effects of RA, R115866 and Liarozole on in vitro cultured ovaries
FOLLICLE COUNT
In order to study the effects of Retinoic acid and RAMBAs on whole ovary development,
B
ovarian
explants cultures were used to investigate the actions of these drugs. Individual
ovaries from newborn mice were cultured for 4 days with 1 μM Liarozole, 0.7 μM
Retinoic acid, 7 μM Retinoic acid or 0.7 μM R115866 with media changes every day.
Histological analysis was then conducted on the ovaries from each treatment group. As
shown in Fig.13, Liarozole and 0.7 μM Retinoic acid promoted the growth and
development of follicles to more advanced stages of development such as primary and
secondary follicles. In addition, the follicles were larger in the ovaries treated with
Liarozole than the control or any other group.
Follicle counting showed a significant decrease in oocyte nests in the groups treated
with R115866, Liarozole and RA as compared to the control. 0.7 μM RA and Liarozole
treated ovaries showed a significant decrease in primordial follicles and ovaries treated
with 0.7 μM RA showed a significant decrease in B/C follicles (Fig.14, 15). However, it
was observed that ovaries cultured with 0.7 μM RA showed a significant increase in
primary follicles and ovaries treated with 0.7 μM RA, R115866 and Liarozole showed a
significant increase in secondary follicles secondary. What was interesting to note was
that atretic follicles were only observed in varies treated with Liarozole. Lastly, the
ovaries treated with Liarozole and 0.7 μM RA showed a significant increase in the total
number of follicles compared to the control (Fig. 14, 15).
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FIG.13: Morphological Analysis in newborn whole ovary sections
Individual ovaries from newborn mice were cultured with 0.7 μM DMSO (A), 1 μM Liarozole
(B), 0.7 μM R115866 (C) and 0.7 μM RA (D) for 4 days with media changes every day. Ovarian
Histology (20X magnification) was determined at the end of culture.
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FIG.14: Identification of follicular stages of development newborn whole ovary sections
Follicle counts were determined on the newborn ovaries at the end of 4 days in culture. Statistical
significance was observed between different treatment groups (*P <0.05, **P<0.005). Data
represented according to different follicle development stages.
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FIG.15: Stages of development categorized by treatment groups
Follicle counts were determined on the newborn ovaries at the end of 4 days in culture. Statistical
significance was observed between different treatment groups (*P <0.05, **P<0.005). Data
represented according to different treatment groups.
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IMMUNOHISTOCHEMISTRY
CYP26B1 Expression
Previous studies have shown that RA is required for growth and differentiation in the
ovary[1]. However, RA induces the expression of CYP26B1 in the ovaries. In order to
better understand and visualize the expression of CYP26B1 during follicle growth and
development in the newborn, whole ovary sections were stained for CYP26B1
expression. For this purpose, ovaries were collected from newborn female mice and
were cultured for 4 days in media containing DMSO that acted as the control, 0.7 μM
R115866, 0.7 μM RA and 1 μM Liarozole. The extent of CYP26B1 expression was
detected using an anti-CYP antibody and the results were monitored and compared with
the negative controls set up for each treatment group as well as with the expression
seen in the other treatment groups.

As expected, CYP26B1 expression was greater in the ovaries treated with 0.7 μM RA, 1
μM Liarozole and 0.7 μM R115866 than the ovaries treated with DMSO (control
group)(Fig. 16). However, ovaries treated with 7 μM of RA showed a lesser extent of
Cyp26b1 than did any other group (data not shown), suggesting that higher doses of
Retinoic acid could be toxic to the ovary.
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FIG.16: CYP26B1 expression in cultured newborn whole ovary sections
Ovaries collected from newborn mice were treated with 0.7 μM DMSO (A), 1 μM
Liarozole (B), 0.7 μM R115866 (C) or 0.7 μM RA (D) in culture media for 4 days. The
expression of CYP26B1 (green) was determined by staining paraffin-embedded ovary
sections with anti-CYP26b1 antibody.
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PRESENCE OF APOPTOSIS

When the ovaries are treated to yield an increase in endogenous RA or administering
exogenous RA, we would expect more cell proliferation and less apoptosis. In order to
test this hypothesis during follicle growth and development in the newborn, whole ovary
sections were stained for apoptosis and cell proliferation, however the cell proliferation
assay didn’t work. In order to evaluate the extent of apoptosis, ovaries were collected
from newborn female mice and were cultured for 4 days in media containing DMSO that
acted as the control, 0.7 μM R115866, 1 μM Liarozole, 0.7 μM RA and 7 μM RA. The
extent of apoptosis was detected using the TUNEL assay and the results were
monitored and compared with the negative controls set up for each treatment group as
well as with the expression seen in the other treatment groups.

It was observed that apoptosis was approximately the same in the ovaries treated with
0.7 μM RA, Liarozole and R115866 as compared to the ovaries treated with DMSO
(control group) (Fig. 17). However, ovaries treated with 7 μM of RA showed a greater
extent of apoptosis than did any other group (data not shown), confirming that higher
doses of Retinoic acid are toxic to the ovary.
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DMSO (0.7μM)
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FIG.17: Apoptosis in newborn whole ovary sections
Ovaries collected from newborn mice were treated with 0.7 μM DMSO (A), 1 μM Liarozole
(B), 0.7 μM R115866 (C) and 0.7 μM RA (D) in culture media for 4 days. The extent of
apoptosis (red) was determined by staining paraffin-embedded ovary sections with the
TUNEL kit, for the detection of apoptosis.
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Discussion
Extensive studies have been performed where it has been demonstrated that both
hormonal and non hormonal factors are necessary for ovarian health and development.
One of these factors has been identified to be Retinoic Acid. Previous studies have
demonstrated that Retinoic acid is required for granulosa cell proliferation and that an
overexpression of Cyp26b1 decreases granulosa cell numbers and induce apoptosis[1].
Conversely, treating cells with a CyP26B1 Inhibitor R115866 shows an increase in cell
proliferation, suggesting the importance of Retinoic acid in the ovary[1].

RA has a moderate effect on follicle development: To further understand the role of RA
in the ovary and on follicle development, studies were performed on follicles isolated
from day 15 ovaries and were treated with RA or RA metabolism blocking agents to
determine the effects of RA on ovary development. By treating the follicles with RA
metabolism blocking agents, endogenous levels of RA can be increased by preventing
its degradation. Studies conducted on follicles showed that direct administration of RA
and indirect increase of RA in culture plays a significant role on follicle growth. It was
seen that RA plays a significant role in follicle development; however, higher doses are
toxic to the growth which is consistent with previous studies of RA. Moderate doses of
RA showed the best growth profile which again is consistent with previous studies.
Stimulatory effects of RA have previously been seen on granulosa cells and the ovary,
however, this study is one of the first to reveal the stimulatory effects of RA on isolated
follicles.
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R115866 showed a significant effect on follicle development: When the follicles were
treated with RA metabolism blocking agent R115866, it was seen that the follicles
showed a dose dependent increase in follicle growth when treated with R115866. The
reason for this increase in follicle growth would be that Cyp26B1 which is responsible
for the degradation of RA in the ovaries is blocked by R115866, thereby increasing the
endogenous RA levels in the ovary. This again is consistent with previous findings on
granulosa cells and supports the findings that Cyp26B1 inhibition leads to increased
growth and proliferation in mouse ovaries.

Liarozole showed a strong stimulatory effect on follicle growth and development
In addition to R115866, the effect of Liarozole was tested on follicle growth. It was seen
that Liarozole increases follicle growth in a dose dependent manner as well. This was
the first time the effect of Liarozole was tested on ovarian development and compared
to the effects of R115866 on follicle growth. What was interesting to note was that
higher doses of Liarozole had a stronger effect on follicle growth than FSH, a known
stimulator of follicle growth. Since Liarozole showed a positive effect on follicle growth, it
was interesting to perform follow up studies on Liarozole and FSH together on follicle
growth. What was also interesting to note that FSH and Liarozole administered in
conjugation had a synergistic effect on follicle growth. Liarozole is an aromatase
inhibitor and a non selective CYP26 inhibitor. This dual action of Liarozole could be a
possible reason for significant follicle growth in culture. Treatment with Liarozole along
with RAR antagonist AGN193109 would help further distinguish the extent to which RA
signaling contributes to Liarozole stimulation of follicle growth.
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Stimulatory effects of RA and Cyp26b1 Inhibitors on whole ovary development: In vitro
studies were also performed on whole newborn ovaries to determine the effects of RA
on newborn ovaries. Morphological studies showed that 0.7 μM Retinoic acid and 1 μm
Liarozole have a greater stimulatory effect on follicle growth when compared to the
ovaries compared to R115866 and the control. The groups treated with Retinoic acid
and Liarozole showed significantly higher numbers of primary and secondary follicles
while those ovaries treated with Liarozole were the only ovaries that showed atretic
follicles. This suggests that RA and Liarozole have a strong stimulatory effect on follicle
development. What was surprising to note was that R115866 did not have as strong an
effect as did the other 2 treatment groups, which can be explained by the fact that
Liarozole has aromatase activity in addition to its Cyp26b1 inhibitory activity which could
potentially be contributing to its action. The results obtained by administering a direct
dose of RA were contradictory to the results obtained via follicle culture, where the
direct administration of RA had a moderate effect on follicle growth; however, this could
be due to the effects of the surrounding granulosa cells that have previously been
shown to undergo proliferation and cell growth upon administering RA. This effect might
have a consequence on the follicle growth as numerous studies have shown the
necessity of regulatory signals passed from the granulosa cells to the follicles for a
healthy growth status.

Cyp26b1 expression was seen throughout the ovary: In order to determine the effects of
RA in the whole cultured ovaries, Cyp26B1 expression was carried out in RA, R115866
and Liarozole treated ovaries. Cyp26B1 expression was high in ovaries treated with 1
3

μM Liarozole and ovaries treated with 0.7 μM R115866 and 0.7 μM RA showed similar

expression signals. This can be explained by the fact that the presence of RA induces
the expression of Cyp26B1 in the body for its degradation, because of which Cyp26B1
expression is expected to be high in all groups, which is what can be seen and is
supported by the results.

Apoptosis was measured amongst treatment groups: In order to determine the extent of
cell death in the three treatment groups, a TUNEL assay was performed on the ovaries.
It was seen that the treated ovaries showed the same extent cell death as the control.
These results were expected as all treatment groups, either directly or indirectly, have
increased levels of RA that have been known to increase cell proliferation and decrease
cell death[1].

High doses of RA are toxic to follicles and granulosa cells: Studies were also performed
wherein ovaries were treated with 7 μM RA (higher dose). These ovaries showed
significantly greater cell death, suggesting that the high dose of RA administered to the
ovary was in fact toxic to the ovary. This could also be a reason why the RA treated
ovaries showed low Cyp26B1 expression. These results confirmed previous studies that
7 μM RA administered to the ovaries was in fact, toxic and led to the production of
unhealthy ovaries.

Several studies have demonstrated the role of RA in the ovaries. The studies have
mostly concentrated on studying the effects of RA on meiosis and the presence of RA in
3

the ovaries and the testes. However, this study provides new insights into the function
and role of RA in individual follicles as well as whole ovaries. In addition, this study also
studies the effects of Cyp26b1 inhibitors such as R115866 and Liarozole, and provides
a comparison of the effects of the drugs on ovary and follicle development. This study
demonstrates that RA is required for follicle development and growth as early as day 0
as well as days 12-16. It also provides further evidence that Cyp26b1 is expressed in
the newborn ovary and that inhibition of Cyp26b1 also promotes cell proliferation and
decreases cell death in the ovary, thereby supporting previous studies of the role of RA
in the ovary.
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